Anson Funds Management’s Ovid Therapeutics OVID Stock Holding History

Anson Funds Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-54,823	Closed	-$176K	–	408
2021 Q4	$176K	Buy	+54,823	New	+$188K	0.02%	314

Other funds holding OVID

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Anson Funds Management's OVID Position: Q1 2022 in Review

Anson Funds Management sold out of Ovid Therapeutics (OVID) in Q1 2022, closing a stake of 54,823 shares — an estimated $176K sold.

Anson Funds Management first reported a position in OVID in Q4 2021 and held it in 1 quarter. The position peaked at $176K in Q4 2021. 62 funds tracked by Wall St. Rank hold OVID as of Q1 2022.

Anson Funds Management reported no remaining Ovid Therapeutics position as of Q1 2022 after selling out during the quarter.
Anson Funds Management sold 54,823 Ovid Therapeutics shares in Q1 2022, an estimated $176K.
Anson Funds Management first reported a position in Ovid Therapeutics in Q4 2021 and held it in 1 quarter.
Anson Funds Management's Ovid Therapeutics position peaked at $176K in Q4 2021.
62 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.